Oruka Therapeutics
Menlo Park, California, United States · Biotechnology, Healthcare, Health Care
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a pr
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Menlo Park, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ORKA)
- Website
- www.orukatx.com
- Company page
Recent activity at Oruka Therapeutics
- : SEC 8-K (8.01): On October 26, 2026, Oruka announced the Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001, a treatment for moderate-to-severe psoriasis (PsO). The trial involved 187 patients and reported significant efficacy results, with 61% of patients in the 600 mg treatment group achieving the primary endpoint of PASI 100 at Week 16, compared to 0% in the placebo group. The results show ORKA-001's favorable safety profile, as no serious treatment-emergent adverse events occurred in the high dose group. Oruka plans to initiate Phase 3 trials in 2027 and expects to report additional trial outcomes soon, indicating a strategic advancement in its PsO treatment portfolio.
- : Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- : SEC 8-K (5.02):
Employee benefit plans
Oruka Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Oruka Therapeutics: questions and answers
What does Oruka Therapeutics do?
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a pr
Where is Oruka Therapeutics headquartered?
Oruka Therapeutics is headquartered in Menlo Park, California, United States.
What is the latest news on Oruka Therapeutics?
On Oct 26, 2026, SEC 8-K (8.01): On October 26, 2026, Oruka announced the Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001, a treatment for moderate-to-severe psoriasis (PsO). The trial involved 187 patients and reported significant efficacy results, with 61% of patients in the 600 mg treatmen
Is Oruka Therapeutics a public company?
Yes. Oruka Therapeutics is publicly traded under the ticker ORKA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy